ClinicalTrials.gg
CompletedNCT04410367PURSUEUpdated Jul 20, 2025Results posted

Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)

A Phase 2 interventional study of 18F fluciclovine in Brain Metastases, sponsored by Blue Earth Diagnostics. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-20.

Sponsored by Blue Earth Diagnostics (part of Bracco) · Phase 2, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,443 studies in Brain Neoplasms with a site in United States — 229 open to participants now, 352 under way, 18 of them phase 3. Brain Neoplasms · United States.

Enrollment
699th of 1,188
23 · median 30
Started
2020
with 42 others
Phase 2
383 of 1,443
51 open now
Registered
1,117th of 1,443
by date

Among the 1,443 studies in Brain Neoplasms with a site in United States, this one is the 699th largest by enrollment of the 1,188 interventional ones that give a count, is one of 43 that started in 2020, is one of 383 in phase 2, and was the 1,117th registered.

Brain Neoplasms

2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

229 of the 1,443 studies in Brain Neoplasms with a site in United States are open now. Recruiting first, the newest first:

224 more — sign in →

All 229 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 425 Brain Neoplasms studies recruiting now, 286 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,443 studies in Brain Neoplasms with a site in United States, or all of them as a file.
02

Study summary

An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy

03

Conditions studied

  • Brain Metastases

Keywords

  • Recurrent Brain Metastases
  • Diagnostic
  • Positron Emission Tomography (PET) Scan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (ECOG) performance status of 0-2
  2. Previous history of solid tumor of any origin
  3. Histopathological confirmation of the primary solid tumor or a site
  4. Previous radiation therapy of brain metastatic lesion(s)
  5. A reference lesion considered by the site investigator to be equivocal for recurrent brain metastasis
  6. Patient requires further confirmatory diagnostic procedures to confirm brain MRI findings and is planned for craniotomy

Exclusion criteria

Exclusion Criteria:

1. Patients with a history of active hematological

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Patients

    Single intravenous administration of 18F fluciclovine for PET Scan

    Drug: 18F fluciclovine

Interventions

  • 18F fluciclovine injection, 185 MegaBecquerel (MBq) (5 Millicurie (mCi)) ± 20%, delivered as an intravenous bolus

    Also known as: Axumin

06

What researchers measure

Primary outcomes

  1. Sensitivity of 18F Fluciclovine PET for Detecting Recurrent Brain Metastases at Different Visual Thresholds

    Sensitivity is calculated as % of participants with positive histopathology who are classified as positive on their 18F fluciclovine PET (i.e. true positive). Each participant had one lesion, therefore results are representative of both subject and lesion level sensitivity. Three readers evaluated the PET scans to classify 18F fluciclovine uptake in study lesions according to 4 incremental categories: absent, mild, moderate or marked. Three different thresholds of 18F fluciclovine uptake were then applied to calculate the sensitivity: Mild or Higher Uptake, Moderate or Higher Uptake, Marked Uptake. As an example, for calculating sensitivity based on the threshold of Mild or Higher Uptake, all participants with positive histopathology, classified by a reader as having mild, moderate or marked 18F fluciclovine uptake, would be categorized as true positive. This calculation was then repeated on the other two threshold categories, to produce sensitivities at different thresholds.

    Time frame: 60 days

  2. Specificity of 18F Fluciclovine PET for Detecting Recurrent Brain Metastases at Different Visual Thresholds

    Specificity is calculated as the % of participants with negative histopathology who are classified as negative on their 18F fluciclovine PET (i.e. true negative). Each participant had 1 lesion, therefore results are representative of both subject and lesion level specificity. 3 readers evaluated the PET scans to classify 18F fluciclovine uptake in study lesions according to 4 incremental categories: absent, mild, moderate or marked. 3 different thresholds of uptake were then applied to calculate the specificity: Mild or Higher Uptake, Moderate or Higher Uptake, Marked Uptake. Example, for calculating specificity based on the threshold of Moderate or Higher Uptake, all participants with negative histopath, classified by a reader as having absent or mild uptake (i.e. not classified by a reader as having moderate or marked uptake), would be categorized as true negative. This calculation was repeated on the other 2 threshold categories, to produce specificities at different thresholds

    Time frame: 60 days

Secondary outcomes

  1. Sensitivity of 18F Fluciclovine PET for Detecting Recurrent Brain Metastases Based on Quantitative and Dynamic Measures of Lesion 18F Fluciclovine Uptake

    Sensitivity calculated as %participants with positive histopath and positive on PET (i.e. true positive). Each participant had 1 lesion, results represent both subject and lesion level sensitivity. Sensitivity is calculated using positive PET classified by quantitative and dynamic measures. Quantitative measure is based on lesion standardized uptake value (SUV). Receiver Operating Characteristic (ROC) analysis of all participant lesion SUV was performed. ROC analyses was performed to select a SUV threshold for calculating sensitivity. Sensitivity calculation: participants with positive histopath and SUV = or \> threshold are positive on scan. Dynamic measure: 3 readers evaluated PET scans to classify uptake pattern based on 4 categories: Type 0, Type I, Type II, Type III. Sensitivity is calculated for each type of uptake pattern (example: calculating sensitivity based on Type I pattern, participants with positive histopath, classified as Type I, would be categorized as true positive).

    Time frame: 60 days

  2. Specificity of Different Thresholds of Quantitative and Dynamic Measures of Lesion 18F Fluciclovine Uptake.

    Specificity is calculated as %participants with negative histopath and negative on PET (i.e. true negative). Each participant had 1 lesion, results represent both subject and lesion level specificity. Specificity is calculated using negative PET classified by quantitative and dynamic measures. Quantitative measure is based on lesion standardized uptake value (SUV). Receiver Operating Characteristic (ROC) analysis of all participant lesion SUV was performed. ROC analyses was performed to select a SUV threshold for calculating sensitivity. Specificity calculation: participants with negative histopath, SUV \< threshold are negative on scan. Dynamic measure: 3 readers evaluated PET scans to classify uptake pattern based on 4 categories: Type 0, Type I, Type II, Type III. Specificity is calculated for each type of uptake pattern (example, calculating specificity based on Type I pattern, participants with negative histopath, classified as Type I, would be categorized as true negative)

    Time frame: 60 days

  3. Treatment-emergent Adverse Events

    Safety will be assessed from data on the occurrence of one or more treatment-emergent Adverse Events from the time of intravenous administration of 18F fluciclovine until 1 day post-18F-fluciclovine administration.

    Time frame: From the time of administration of 18F fluciclovine until 1 day post-18F-fluciclovine administration.

07

Results

Posted Aug 1, 2023

Participant flow

Subjects with a history of brain metastases previously treated with primary, adjuvant, or repeat (salvage) radiation therapy, with a recent standard of care (SoC) brain magnetic resonance imaging (MRI) found to be equivocal for recurrent brain metastasis, and who met all the inclusion criteria and none of the exclusion criteria, were consented and enrolled. Subjects were screened between 28Oct2020 and 30Dec2021. Nine clinical research sites in the US participated in the study.

Participant flow — Overall Study
Milestone18F-Fluciclovine Injection
Started23
Underwent 18f-fluciclovine pet23
Completed23
Not completed0

Outcome measures

PrimarySensitivity of 18F Fluciclovine PET for Detecting Recurrent Brain Metastases at Different Visual Thresholds

Sensitivity is calculated as % of participants with positive histopathology who are classified as positive on their 18F fluciclovine PET (i.e. true positive). Each participant had one lesion, therefore results are representative of both subject and lesion level sensitivity. Three readers evaluated the PET scans to classify 18F fluciclovine uptake in study lesions according to 4 incremental categories: absent, mild, moderate or marked. Three different thresholds of 18F fluciclovine uptake were then applied to calculate the sensitivity: Mild or Higher Uptake, Moderate or Higher Uptake, Marked Uptake. As an example, for calculating sensitivity based on the threshold of Mild or Higher Uptake, all participants with positive histopathology, classified by a reader as having mild, moderate or marked 18F fluciclovine uptake, would be categorized as true positive. This calculation was then repeated on the other two threshold categories, to produce sensitivities at different thresholds.

Time frame:
60 days
Reported as:
Number · percentage of participants
Sensitivity of 18F Fluciclovine PET for Detecting Recurrent Brain Metastases at Different Visual Thresholds
percentage of participants18F-Fluciclovine Injection
Mild or Higher Uptake = Positive : Central Reader 1100 (69.2 to 100)
Mild or Higher Uptake = Positive : Central Reader 2100 (69.2 to 100)
Mild or Higher Uptake = Positive : Central Reader 3100 (69.2 to 100)
Moderate or Higher Uptake = Positive : Central Reader 1100 (69.2 to 100)
Moderate or Higher Uptake = Positive : Central Reader 2100 (69.2 to 100)
Moderate or Higher Uptake = Positive : Central Reader 390 (55.5 to 99.8)
Marked Uptake = Positive : Central Reader 180 (44.4 to 97.5)
Marked Uptake = Positive : Central Reader 240 (12.2 to 73.8)
Marked Uptake = Positive : Central Reader 360 (26.2 to 87.8)
PrimarySpecificity of 18F Fluciclovine PET for Detecting Recurrent Brain Metastases at Different Visual Thresholds

Specificity is calculated as the % of participants with negative histopathology who are classified as negative on their 18F fluciclovine PET (i.e. true negative). Each participant had 1 lesion, therefore results are representative of both subject and lesion level specificity. 3 readers evaluated the PET scans to classify 18F fluciclovine uptake in study lesions according to 4 incremental categories: absent, mild, moderate or marked. 3 different thresholds of uptake were then applied to calculate the specificity: Mild or Higher Uptake, Moderate or Higher Uptake, Marked Uptake. Example, for calculating specificity based on the threshold of Moderate or Higher Uptake, all participants with negative histopath, classified by a reader as having absent or mild uptake (i.e. not classified by a reader as having moderate or marked uptake), would be categorized as true negative. This calculation was repeated on the other 2 threshold categories, to produce specificities at different thresholds

Time frame:
60 days
Reported as:
Number · percentage of participants
Specificity of 18F Fluciclovine PET for Detecting Recurrent Brain Metastases at Different Visual Thresholds
percentage of participants18F-Fluciclovine Injection
Mild or Higher Uptake = Positive : Central Reader 10 (0.0 to 24.7)
Mild or Higher Uptake = Positive : Central Reader 20 (0.0 to 24.7)
Mild or Higher Uptake = Positive : Central Reader 30 (0.0 to 24.7)
Moderate or Higher Uptake = Positive : Central Reader 138.5 (13.9 to 68.4)
Moderate or Higher Uptake = Positive : Central Reader 230.8 (9.1 to 61.4)
Moderate or Higher Uptake = Positive : Central Reader 346.2 (19.2 to 74.9)
Marked Uptake = Positive : Central Reader 192.3 (64.0 to 99.8)
Marked Uptake = Positive : Central Reader 2100 (75.3 to 100.0)
Marked Uptake = Positive : Central Reader 3100 (75.3 to 100.0)
SecondarySensitivity of 18F Fluciclovine PET for Detecting Recurrent Brain Metastases Based on Quantitative and Dynamic Measures of Lesion 18F Fluciclovine Uptake

Sensitivity calculated as %participants with positive histopath and positive on PET (i.e. true positive). Each participant had 1 lesion, results represent both subject and lesion level sensitivity. Sensitivity is calculated using positive PET classified by quantitative and dynamic measures. Quantitative measure is based on lesion standardized uptake value (SUV). Receiver Operating Characteristic (ROC) analysis of all participant lesion SUV was performed. ROC analyses was performed to select a SUV threshold for calculating sensitivity. Sensitivity calculation: participants with positive histopath and SUV = or \> threshold are positive on scan. Dynamic measure: 3 readers evaluated PET scans to classify uptake pattern based on 4 categories: Type 0, Type I, Type II, Type III. Sensitivity is calculated for each type of uptake pattern (example: calculating sensitivity based on Type I pattern, participants with positive histopath, classified as Type I, would be categorized as true positive).

Time frame:
60 days
Reported as:
Number · percentage of participants
Sensitivity of 18F Fluciclovine PET for Detecting Recurrent Brain Metastases Based on Quantitative and Dynamic Measures of Lesion 18F Fluciclovine Uptake
percentage of participants18F-Fluciclovine Injection
Quantitative SUV ≥ 4.8 = Positive : Central Reader 180 (44.4 to 97.5)
Quantitative SUV ≥ 4.8 = Positive : Central Reader 280 (44.4 to 97.5)
Quantitative SUV ≥ 4.8 = Positive : Central Reader 380 (44.4 to 97.5)
Dynamic Type 0: Central Reader 10 (0 to 30.9)
Dynamic Type 0 : Central Reader 20 (0 to 30.9)
Dynamic Type 0 : Central Reader 30 (0 to 30.9)
Dynamic Type I: Central Reader 180 (44.4 to 97.5)
Dynamic Type I: Central Reader 290 (55.5 to 99.8)
Dynamic Type I: Central Reader 3100 (69.2 to 100)
Dynamic Type II: Central Reader 110 (0.3 to 44.5)
Dynamic Type II: Central Reader 210 (0.3 to 44.5)
Dynamic Type II: Central Reader 30 (0 to 30.9)
Dynamic Type III: Central Reader 110 (0.3 to 44.5)
Dynamic Type III: Central Reader 20 (0 to 30.9)
Dynamic Type III: Central Reader 30 (0 to 30.9)
SecondarySpecificity of Different Thresholds of Quantitative and Dynamic Measures of Lesion 18F Fluciclovine Uptake.

Specificity is calculated as %participants with negative histopath and negative on PET (i.e. true negative). Each participant had 1 lesion, results represent both subject and lesion level specificity. Specificity is calculated using negative PET classified by quantitative and dynamic measures. Quantitative measure is based on lesion standardized uptake value (SUV). Receiver Operating Characteristic (ROC) analysis of all participant lesion SUV was performed. ROC analyses was performed to select a SUV threshold for calculating sensitivity. Specificity calculation: participants with negative histopath, SUV \< threshold are negative on scan. Dynamic measure: 3 readers evaluated PET scans to classify uptake pattern based on 4 categories: Type 0, Type I, Type II, Type III. Specificity is calculated for each type of uptake pattern (example, calculating specificity based on Type I pattern, participants with negative histopath, classified as Type I, would be categorized as true negative)

Time frame:
60 days
Reported as:
Number · percentage of participants
Specificity of Different Thresholds of Quantitative and Dynamic Measures of Lesion 18F Fluciclovine Uptake.
percentage of participants18F-Fluciclovine Injection
SUV ≥ 4.8 : Central Reader 184.6 (54.6 to 98.1)
SUV ≥ 4.8 : Central Reader 284.6 (54.6 to 98.1)
SUV ≥ 4.8 : Central Reader 384.6 (54.6 to 98.1)
Dynamic Type 0 : Central Reader 1100 (75.3 to 100)
Dynamic Type 0 : Central Reader 2100 (75.3 to 100)
Dynamic Type 0 : Central Reader 3100 (75.3 to 100)
Dynamic Type I : Central Reader 17.7 (0.2 to 36.0)
Dynamic Type I : Central Reader 215.4 (1.9 to 45.5)
Dynamic Type I : Central Reader 30 (0 to 24.7)
Dynamic Type II : Central Reader 192.3 (64.0 to 99.8)
Dynamic Type II : Central Reader 284.6 (54.6 to 98.1)
Dynamic Type II : Central Reader 3100 (75.3 to 100)
Dynamic Type III : Central Reader 1100 (75.3 to 100)
Dynamic Type III : Central Reader 2100 (75.3 to 100)
Dynamic Type III : Central Reader 3100 (75.3 to 100)
SecondaryTreatment-emergent Adverse Events

Safety will be assessed from data on the occurrence of one or more treatment-emergent Adverse Events from the time of intravenous administration of 18F fluciclovine until 1 day post-18F-fluciclovine administration.

Time frame:
From the time of administration of 18F fluciclovine until 1 day post-18F-fluciclovine administration.
Reported as:
Count of participants · Participants
Treatment-emergent Adverse Events
Participants18F-Fluciclovine Injection
Subjects reporting at least 1 TEAE1
Nervous System Disorders (Headache)1

Adverse events

Collected over Safety was assessed from the time of 18F-fluciclovine administration until 1 day post18Ffluciclovine administration based on reported adverse events (AEs) and serious adverse events (SAEs); treatment emergent adverse events (TEAE).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
18F-Fluciclovine Injection0/23 (0%)0/23 (0%)1/23 (4.3%)
Most frequent other events
Most frequent other events
Event18F-Fluciclovine Injection
HeadacheNervous system disorders1/23

Baseline characteristics

Age, Continuous
Age, Continuous(years)Patients
Mean59.8 ± 11.88
Sex: Female, Male
Sex: Female, Male(Participants)Patients
Female16
Male7
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Patients
Hispanic or Latino8
Not Hispanic or Latino15
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Patients
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White20
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Patients
United States23
08

Study locations

9 sites
  • John Wayne Cancer Institute at Providence St. John's Health Center
    Santa Monica, California 90404, United States
  • Yale School of Medicine
    New Haven, Connecticut 06519, United States
  • Miami Cancer Institute
    Miami, Florida 33176, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70131, United States
  • Washington University School of Medicine Center for Clinical Imaging Research
    St Louis, Missouri 63110, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • University Hospital Cleveland
    Cleveland, Ohio 44106, United States
  • University of Pennsylvania Health System
    Philadelphia, Pennsylvania 19104, United States
  • Center for Quantitative Cancer Imaging at Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
09

References and documents

Publications

  • Kotecha R, Aboian M, Nabavizadeh SA, Parent EE, Trifiletti DM, Chao ST. Letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group": 18F-fluciclovine and target volume delineation. Neuro Oncol. 2021 Aug 2;23(8):1408-1409. doi: 10.1093/neuonc/noab097. No abstract available. PubMed 34081125 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Dec 2021, 16 months.

Results were first posted in Aug 2023, 1 year 7 months after primary completion.

Of 44 industry-sponsored phase 2 interventional studies under Brain Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's 16 months is below that.

Counting every sponsor, half of 252 studies reached it within 61 months; a quarter within 38 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2020
First posted
Jun 1, 2020
StartActual
Aug 31, 2020
Primary completionActual
Dec 31, 2021
CompletionActual
Dec 31, 2021
Results first posted
Aug 1, 2023
Last update
Jul 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04410367
Collaborators
Precision For Medicine
Responsible party
Sponsor
First posted
Jun 1, 2020
Start date
Aug 31, 2020
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021
Results posted
Aug 1, 2023
Last update
Jul 20, 2025

Study contacts

Eugene Teoh, MD
study director · Blue Earth Diagnostics
Rupesh Kotecha, MD
principal investigator · Miami Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluciclovine F-18

Start the discussion